vs
Castellum, Inc.（CTM）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Castellum, Inc.的季度营收约是Protalix BioTherapeutics, Inc.的1.4倍（$12.6M vs $9.1M），Castellum, Inc.净利率更高（-10.5% vs -60.3%，领先49.8%），Castellum, Inc.同比增速更快（21.9% vs -49.9%），过去两年Castellum, Inc.的营收复合增速更高（5.3% vs -6.7%）
Castellum, Inc.是一家总部位于美国的网络安全与信息技术服务提供商，服务覆盖国防政府机构、公共部门及商业企业客户，提供威胁检测、数据保护、云安全及托管IT解决方案，助力客户防范网络风险、保护核心数字资产。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
CTM vs PLX — 直观对比
营收规模更大
CTM
是对方的1.4倍
$9.1M
营收增速更快
CTM
高出71.9%
-49.9%
净利率更高
CTM
高出49.8%
-60.3%
两年增速更快
CTM
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $12.6M | $9.1M |
| 净利润 | $-1.3M | $-5.5M |
| 毛利率 | 33.9% | 49.4% |
| 营业利润率 | -11.1% | -51.1% |
| 净利率 | -10.5% | -60.3% |
| 营收同比 | 21.9% | -49.9% |
| 净利润同比 | 51.8% | -184.8% |
| 每股收益（稀释后） | $-0.02 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTMPLX
| Q4 25 | $12.6M | $9.1M | ||
| Q3 25 | $14.6M | $17.9M | ||
| Q2 25 | $14.0M | $15.7M | ||
| Q1 25 | $11.7M | $10.1M | ||
| Q4 24 | $10.3M | $18.2M | ||
| Q3 24 | $11.6M | $18.0M | ||
| Q2 24 | $11.5M | $13.5M | ||
| Q1 24 | $11.3M | — |
净利润CTMPLX
| Q4 25 | $-1.3M | $-5.5M | ||
| Q3 25 | $415.4K | $2.4M | ||
| Q2 25 | $-322.1K | $164.0K | ||
| Q1 25 | $-1.2M | $-3.6M | ||
| Q4 24 | $-2.7M | $6.5M | ||
| Q3 24 | $-1.3M | $3.2M | ||
| Q2 24 | $-1.8M | $-2.2M | ||
| Q1 24 | $-4.1M | — |
毛利率CTMPLX
| Q4 25 | 33.9% | 49.4% | ||
| Q3 25 | 37.6% | 53.4% | ||
| Q2 25 | 36.1% | 62.5% | ||
| Q1 25 | 39.0% | 19.1% | ||
| Q4 24 | 40.0% | 78.7% | ||
| Q3 24 | 42.7% | 53.4% | ||
| Q2 24 | 40.6% | 29.8% | ||
| Q1 24 | 39.8% | — |
营业利润率CTMPLX
| Q4 25 | -11.1% | -51.1% | ||
| Q3 25 | 3.0% | 11.9% | ||
| Q2 25 | -2.7% | 7.5% | ||
| Q1 25 | -12.7% | -41.0% | ||
| Q4 24 | -15.7% | 39.6% | ||
| Q3 24 | -11.9% | 22.2% | ||
| Q2 24 | -13.6% | -18.0% | ||
| Q1 24 | -23.6% | — |
净利率CTMPLX
| Q4 25 | -10.5% | -60.3% | ||
| Q3 25 | 2.8% | 13.2% | ||
| Q2 25 | -2.3% | 1.0% | ||
| Q1 25 | -10.0% | -35.8% | ||
| Q4 24 | -26.6% | 35.6% | ||
| Q3 24 | -11.0% | 18.0% | ||
| Q2 24 | -16.0% | -16.4% | ||
| Q1 24 | -36.3% | — |
每股收益（稀释后）CTMPLX
| Q4 25 | $-0.02 | $-0.06 | ||
| Q3 25 | $0.00 | $0.03 | ||
| Q2 25 | $0.00 | $0.00 | ||
| Q1 25 | $-0.01 | $-0.05 | ||
| Q4 24 | $-0.05 | $0.10 | ||
| Q3 24 | $-0.02 | $0.03 | ||
| Q2 24 | $-0.03 | $-0.03 | ||
| Q1 24 | $-0.08 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $35.8M | $48.2M |
| 总资产 | $41.9M | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTMPLX
| Q4 25 | — | $14.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $17.9M | ||
| Q1 25 | — | $19.5M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | — | $23.4M | ||
| Q1 24 | — | — |
总债务CTMPLX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $8.0M | — | ||
| Q3 24 | $8.3M | — | ||
| Q2 24 | $8.7M | — | ||
| Q1 24 | $9.0M | — |
股东权益CTMPLX
| Q4 25 | $35.8M | $48.2M | ||
| Q3 25 | $36.7M | $52.9M | ||
| Q2 25 | $31.8M | $49.9M | ||
| Q1 25 | $26.1M | $45.2M | ||
| Q4 24 | $20.2M | $43.2M | ||
| Q3 24 | $12.0M | $32.4M | ||
| Q2 24 | $12.1M | $28.6M | ||
| Q1 24 | $12.8M | — |
总资产CTMPLX
| Q4 25 | $41.9M | $82.3M | ||
| Q3 25 | $46.3M | $82.3M | ||
| Q2 25 | $43.4M | $78.5M | ||
| Q1 25 | $41.1M | $73.9M | ||
| Q4 24 | $37.8M | $73.4M | ||
| Q3 24 | $28.8M | $61.6M | ||
| Q2 24 | $29.5M | $91.5M | ||
| Q1 24 | $30.5M | — |
负债/权益比CTMPLX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.40× | — | ||
| Q3 24 | 0.69× | — | ||
| Q2 24 | 0.72× | — | ||
| Q1 24 | 0.70× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-661.7K | $2.0M |
| 自由现金流经营现金流 - 资本支出 | — | $1.6M |
| 自由现金流率自由现金流/营收 | — | 17.8% |
| 资本支出强度资本支出/营收 | — | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-13.6M |
8季度趋势，按日历期对齐
经营现金流CTMPLX
| Q4 25 | $-661.7K | $2.0M | ||
| Q3 25 | $1.0M | $-3.7M | ||
| Q2 25 | $214.2K | $-5.2M | ||
| Q1 25 | $-2.5M | $-5.1M | ||
| Q4 24 | $-394.4K | $4.0M | ||
| Q3 24 | $742.2K | $4.1M | ||
| Q2 24 | $748.6K | $-3.6M | ||
| Q1 24 | $23.7K | — |
自由现金流CTMPLX
| Q4 25 | — | $1.6M | ||
| Q3 25 | $957.0K | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | $738.9K | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
自由现金流率CTMPLX
| Q4 25 | — | 17.8% | ||
| Q3 25 | 6.5% | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | 6.4% | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
资本支出强度CTMPLX
| Q4 25 | — | 4.4% | ||
| Q3 25 | 0.3% | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | 0.0% | 2.3% | ||
| Q3 24 | 0.0% | 0.5% | ||
| Q2 24 | 0.0% | 1.3% | ||
| Q1 24 | 0.0% | — |
现金转化率CTMPLX
| Q4 25 | — | — | ||
| Q3 25 | 2.41× | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTM
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
